These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26994242)

  • 21. Perinatal diagnosis of malignant hyperthermia susceptibility.
    Girard T; Jöhr M; Schaefer C; Urwyler A
    Anesthesiology; 2006 Jun; 104(6):1353-4. PubMed ID: 16732128
    [No Abstract]   [Full Text] [Related]  

  • 22. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
    Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
    Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myopathic changes in malignant hyperthermia-susceptible patients.
    Rosenberg H
    Can J Anaesth; 2013 Oct; 60(10):955-9. PubMed ID: 23897489
    [No Abstract]   [Full Text] [Related]  

  • 24. The genetics of malignant hyperthermia.
    Brandom BW
    Anesthesiol Clin North Am; 2005 Dec; 23(4):615-9, viii. PubMed ID: 16310654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A fulminant malignant hyperthermia episode in a patient with ryanodine receptor gene mutation p.Tyr522Ser.
    Girard T; Suhner M; Levano S; Singer M; Zollinger A; Hofer CK
    Anesth Analg; 2008 Dec; 107(6):1953-5. PubMed ID: 19020143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. XXIVth Annual Meeting of the European Malignant Hyperthermia Group.
    Brandom BW; Muldoon SM
    Anesthesiology; 2005 Dec; 103(6):1324. PubMed ID: 16306761
    [No Abstract]   [Full Text] [Related]  

  • 27. The practicality and need for genetic testing for malignant hyperthermia.
    Brandom BW; Muldoon SM
    Anesthesiology; 2005 Nov; 103(5):1100; author reply 1101. PubMed ID: 16249688
    [No Abstract]   [Full Text] [Related]  

  • 28. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Malignant hyperthermia as a complication of anesthesia: predisposition is hereditary].
    Snoeck MM; Gielen MJ; Sengers RC; Padberg GW; Iles DE; Booij LH
    Ned Tijdschr Geneeskd; 1997 Mar; 141(13):616-9. PubMed ID: 9190536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.
    van den Bersselaar LR; Hellblom A; Gashi M; Kamsteeg EJ; Voermans NC; Jungbluth H; de Puydt J; Heytens L; Riazi S; Snoeck MMJ
    Anesthesiology; 2022 Jun; 136(6):940-953. PubMed ID: 35285867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular genetic testing to diagnose malignant hyperthermia susceptibility.
    Girard T; Litman RS
    J Clin Anesth; 2008 May; 20(3):161-3. PubMed ID: 18502356
    [No Abstract]   [Full Text] [Related]  

  • 32. Difficult diagnosis of malignant hyperthermia during laparoscopic surgery.
    Freiermuth D; Poblete B; Singer M; Konrad CJ; Girard T
    Eur J Anaesthesiol; 2013 Oct; 30(10):635-8. PubMed ID: 23736090
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mathematical model to improve on phenotyping for molecular genetic research in malignant hyperthermia.
    Ginz HF; Rüffert H; Levano S; Li Wan Po A; Benthien J; Urwyler A; Girard T
    Pharmacogenet Genomics; 2009 Dec; 19(12):972-8. PubMed ID: 19890226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ryanodine on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Muldoon S; Bünger R
    Eur J Anaesthesiol; 2008 Jan; 25(1):48-57. PubMed ID: 17686208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of the ryanodine 1 gene for malignant hyperthermia causative mutations by high resolution melt curve analysis.
    Broman M; Heinecke K; Islander G; Schuster F; Glahn K; Bodelsson M; Treves S; Müller C
    Anesth Analg; 2011 Nov; 113(5):1120-8. PubMed ID: 21965348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.